Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,348.00 GBX | -4.60% |
|
-4.30% | +0.11% |
09:49pm | FTSE 100 logs fourth straight week of gains on rate cut optimism, earnings | RE |
09:49pm | FTSE 100 logs fourth straight week of gains on rate cut optimism, earnings | RE |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 66,801 | 80,458 | 58,381 | 59,112 | 54,944 | 57,117 | - | - |
Change | - | 20.44% | -27.44% | 1.25% | -7.05% | 3.95% | - | - |
Enterprise Value (EV) 1 | 87,581 | 1,00,296 | 75,578 | 74,152 | 68,039 | 70,837 | 68,371 | 65,534 |
Change | - | 14.52% | -24.65% | -1.89% | -8.24% | 4.11% | -3.48% | -4.15% |
P/E ratio | 11.8x | 18.6x | 3.93x | 11.9x | 21.3x | 10x | 8.96x | 8.34x |
PBR | 4.58x | 5.34x | 5.47x | 4.4x | 4.02x | 3.87x | 3.21x | 2.71x |
PEG | - | -0.8x | 0x | -0.2x | -0.4x | 0x | 0.8x | 1.12x |
Capitalization / Revenue | 1.96x | 2.36x | 1.99x | 1.95x | 1.75x | 1.79x | 1.7x | 1.62x |
EV / Revenue | 2.57x | 2.94x | 2.58x | 2.45x | 2.17x | 2.22x | 2.03x | 1.86x |
EV / EBITDA | 9.19x | 8.85x | 7.23x | 6.37x | 6.36x | 6.58x | 5.84x | 5.28x |
EV / EBIT | 9.83x | 11.4x | 9.27x | 8.44x | 7.44x | 7.45x | 6.61x | 5.94x |
EV / FCF | 16.2x | 22.6x | 12.1x | 13.6x | 13x | 15.4x | 10.5x | 9.3x |
FCF Yield | 6.17% | 4.42% | 8.28% | 7.36% | 7.67% | 6.48% | 9.51% | 10.7% |
Dividend per Share 2 | 1 | 1 | 0.6125 | 0.58 | 0.61 | 0.6506 | 0.6916 | 0.7349 |
Rate of return | 5.96% | 4.98% | 4.26% | 4% | 4.53% | 4.6% | 4.89% | 5.2% |
EPS 2 | 1.426 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.577 | 1.695 |
Distribution rate | 70.1% | 92.4% | 16.7% | 47.7% | 96.5% | 46.1% | 43.8% | 43.4% |
Net sales 1 | 34,099 | 34,114 | 29,324 | 30,328 | 31,376 | 31,965 | 33,618 | 35,195 |
EBITDA 1 | 9,530 | 11,330 | 10,449 | 11,635 | 10,693 | 10,764 | 11,707 | 12,417 |
EBIT 1 | 8,906 | 8,806 | 8,151 | 8,786 | 9,148 | 9,514 | 10,342 | 11,042 |
Net income 1 | 5,749 | 4,385 | 14,956 | 4,928 | 2,575 | 5,656 | 6,343 | 6,755 |
Net Debt 1 | 20,780 | 19,838 | 17,197 | 15,040 | 13,095 | 13,720 | 11,254 | 8,417 |
Reference price 2 | 16.78 | 20.08 | 14.38 | 14.50 | 13.46 | 14.13 | 14.13 | 14.13 |
Nbr of stocks (in thousands) | 39,82,185 | 40,06,383 | 40,60,999 | 40,76,145 | 40,80,519 | 40,42,229 | - | - |
Announcement Date | 03/02/21 | 09/02/22 | 01/02/23 | 31/01/24 | 05/02/25 | - | - | - |
1GBP in Million2GBP
Estimates
P/E ratio, Detailed evolution
P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
---|---|---|---|---|---|---|
10.02x | 2.22x | 6.58x | 4.6% | 7.66TCr | ||
35.65x | 11.83x | 26.89x | 0.78% | 68TCr | ||
14.69x | 4.3x | 11.77x | 3.13% | 39TCr | ||
27.44x | 6.55x | 13.83x | 3.42% | 34TCr | ||
16.3x | 5.91x | 11.82x | 3.11% | 29TCr | ||
14.17x | 3.49x | 8.63x | 3.84% | 26TCr | ||
16.53x | 4.37x | 10.34x | 3.47% | 22TCr | ||
21.77x | 4.07x | 11.98x | 2.32% | 21TCr | ||
10.44x | 3.39x | 7.33x | 3.95% | 20TCr | ||
22.81x | 5.82x | 11.23x | 3.22% | 16TCr | ||
Average | 18.98x | 5.19x | 12.04x | 3.18% | 28.43TCr | |
Weighted average by Cap. | 22.07x | 6.42x | 14.79x | 2.73% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition